Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Dinoprostone Administration Prior to an Intrauterine Device Insertion in Multiparous Women.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* multiparous women aged over 18 years of age requesting an IUD for contraception, had a negative pregnancy test.~Exclusion Criteria:~* currently pregnant or were pregnant within 6 weeks of study entry~* had a prior attempted or successful IUD insertion~* had a history of a cervical procedure such as cone biopsy, Loop electrosurgical excision procedure, or cryotherapy~* any World Health Organization Medical Eligibility Criteria category 3 or 4 precaution to an IUD~* active vaginitis or cervicitis~* undiagnosed abnormal uterine bleeding~* pelvic inﬂammatory disease within the last 3 months~* ﬁbroids or other uterine abnormalities distorting the uterine cavity~* contraindication or allergy to dinoprostone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- dinoprostone (Type: EXPERIMENTAL): 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.
- placebo (Type: PLACEBO_COMPARATOR): one tablet of placebo self-inserted by the patients 3 hours before the scheduled IUD insertion appointment.

Based on this trial design, predict the completion outcome and termination type (if applicable).